In the September edition of the Hardman Monthly Newsletter, Dr Martin Hall - based partly on his personal experiences as a long-standing investment analyst - addresses various accounting issues that are highly relevant to today's investors. In particular, he concludes that measuring company cash flow - and especially projecting future cash flows - is pivotal to undertaking rigorous financial analysis, irrespective of how individual companies may present it.
04 Sep 2017
The Monthly September 2017
Abzena (ABZA:LON), 0 | Allergy Therapeutics plc (AGY:LON), 3.2 | Alliance Pharma plc (APH:LON), 35.1 | Arbuthnot Banking Group PLC (ARBB:LON), 1,025 | Avacta Group PLC (AVCT:LON), 44.2 | Burford Capital Limited (BUR:LON), 0 | Chamberlin plc (CMH:LON), 1.2 | TheraCryf PLC (TCF:LON), 0.8 | Murgitroyd Group (MUR:LON), 0 | Woodbois Limited (WBI:LON), 0 | Cambridge Nutritional Sciences PLC (CNSL:LON), 3.9 | PPHE Hotel Group Limited (PPH:LON), 1,455 | Primary Health Properties PLC (PHP:LON), 97.1 | R.E.A. Holdings plc (RE:LON), 83.8 | Scancell Holdings Plc (SCLP:LON), 0 | Surface Transforms PLC (SCE:LON), 1.2 | Tissue Regenix Group plc (TRX:LON), 61.5 | Oxford BioMedica plc (OXB:LON), 324 | ValiRx PLC (VAL:LON), 1.9
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
The Monthly September 2017
Abzena (ABZA:LON), 0 | Allergy Therapeutics plc (AGY:LON), 3.2 | Alliance Pharma plc (APH:LON), 35.1 | Arbuthnot Banking Group PLC (ARBB:LON), 1,025 | Avacta Group PLC (AVCT:LON), 44.2 | Burford Capital Limited (BUR:LON), 0 | Chamberlin plc (CMH:LON), 1.2 | TheraCryf PLC (TCF:LON), 0.8 | Murgitroyd Group (MUR:LON), 0 | Woodbois Limited (WBI:LON), 0 | Cambridge Nutritional Sciences PLC (CNSL:LON), 3.9 | PPHE Hotel Group Limited (PPH:LON), 1,455 | Primary Health Properties PLC (PHP:LON), 97.1 | R.E.A. Holdings plc (RE:LON), 83.8 | Scancell Holdings Plc (SCLP:LON), 0 | Surface Transforms PLC (SCE:LON), 1.2 | Tissue Regenix Group plc (TRX:LON), 61.5 | Oxford BioMedica plc (OXB:LON), 324 | ValiRx PLC (VAL:LON), 1.9
- Published:
04 Sep 2017 -
Author:
Martin Hall -
Pages:
44
In the September edition of the Hardman Monthly Newsletter, Dr Martin Hall - based partly on his personal experiences as a long-standing investment analyst - addresses various accounting issues that are highly relevant to today's investors. In particular, he concludes that measuring company cash flow - and especially projecting future cash flows - is pivotal to undertaking rigorous financial analysis, irrespective of how individual companies may present it.